Competition & Markets Authority
CMA welcomes EU Court ruling in pay-for-delay drug case
The CMA welcomes a ruling from the EU Court of Justice in relation to its case that drug companies supplying an antidepressant called paroxetine broke the law.
The ruling, released today, follows appeals from GlaxoSmithKline and other pharmaceutical companies against the Competition and Markets Authority’s (CMA) decision that they had broken competition law. The CMA imposed fines of £45 million on the companies involved.
This ruling has clarified a number of important questions and will help competition authorities, including the CMA, in their work to tackle this harmful behaviour by pharmaceutical companies.
In 2016 the CMA found that GlaxoSmithKline had agreed to make payments totalling over £50 million to other generic suppliers of paroxetine. These payments were aimed at delaying the potential entry of these competitors into the UK market.
The CMA found these ‘pay-for-delay’ agreements deferred the threat of increased competition, and potentially deprived the NHS of the significant price falls that generally result from generic competition. In this case, when independent generic entry eventually took place, average paroxetine prices dropped by over 70% in 2 years.
Following today’s ruling, the case will now go back to the Competition Appeal Tribunal for a final judgment on the appeals.
Andrea Coscelli, Chief Executive at the CMA, said:
“This case shows our ongoing determination to take action against illegal behaviour by drug companies designed to stifle competition at the expense of the NHS. This has been a lengthy process, and we look forward to the CAT’s final judgment.
“Cracking down on harmful behaviour, such as pay-for-delay agreements, is essential to protect the NHS – and so UK taxpayers - from paying more than they should for an important medicine.”
The CMA currently has other, unrelated investigations open in relation to 7 other pharmaceutical drugs.
More information on this investigation can be found on the Paroxetine investigation case page.
Notes to Editors:
- In 2016 GlaxoSmithKline and the generic suppliers – including GUK and Alpharma – appealed the CMA’s decision to the Competition Appeal Tribunal (CAT).
- The CAT then referred a series of questions to the Court of Justice of the European Union (under Article 267 of the Treaty on the Functioning of the European Union) about the application of law to these types of ‘pay for delay’ agreement.
- Today’s judgment follows the opinion from Advocate General Kokott from the Court of Justice of the European Union issued on 22 January.
- The payments made by GSK to the generic companies consisted of cash and other non-cash value transfers.
- Appeals against the CMA’s decision were brought by Glaxosmithkline Plc, Generics (UK) Limited, Xellia Pharmaceuticals APS/Alpharma LLC, Actavis UK Limited and Merck KGAA.
Latest News from
Competition & Markets Authority
CMA acts to protect competition on UK-US airline routes18/09/2020 09:20:00
Due to coronavirus, the CMA has imposed measures to protect competition on UK-US air routes while it investigates an agreement involving BA and American Airlines.
Motorcycle insurance broker merger raises competition concerns17/09/2020 09:20:00
The CMA has found that Ardonagh’s completed purchase of Bennetts could lead to higher prices, less choice and worse services for motorcyclists in the UK.
TUI UK to complete refunds by the end of the month16/09/2020 12:25:00
TUI UK has committed to the CMA that customers awaiting their refunds for holidays that were cancelled due to coronavirus will receive them by the end of the month.
Final decision published in window blind merger inquiry15/09/2020 09:20:00
The CMA has decided that Hunter Douglas, owner of online blinds retailer Blinds2Go, must sell the majority of its shares in 247 to protect competition and prevent higher prices.
Digital advertising merger to be abandoned during CMA investigation14/09/2020 13:25:00
Taboola has announced that it is to abandon its proposed purchase of Outbrain.
CMA updates competition law risk guide for managers11/09/2020 09:20:00
An updated guide to competition rules has been issued to help managers, directors and their advisers to stay on the right side of the law.
CMA to assess progress in legal services sector10/09/2020 09:20:00
The CMA is reviewing the legal services sector in England and Wales to assess whether transparency of price, quality and service have improved.
Reseller GAK fined for illegally agreeing not to discount online09/09/2020 14:15:00
Lessons from the CMA’s investigation into GAK and Yamaha's use of illegal resale price maintenance (RPM).